Clinical Trial Update: An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). [Phase 3]

View source ↗

Summary

Extension treatment protocol for participants from a Phase 3 trial comparing tivozanib vs sorafenib in advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Tivozanib (tivozanib)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Advanced Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-10-05